Vident Advisory LLC Sells 5,204 Shares of Stryker Corporation $SYK

Key Points

• Vident Advisory LLC reduced its stake in Stryker Corporation by 27.6% in the first quarter, owning 13,669 shares valued at approximately $5.09 million after selling 5,204 shares.
• Significant increases in ownership of Stryker shares were observed from other institutional investors, including Vanguard Group and Price T Rowe Associates, with Vanguard owning over $12 billion worth of shares after a 1.1% increase.
• Stryker recently announced a quarterly dividend of $0.84 per share, resulting in an annual yield of 0.9% and a payout ratio of 44.50%.

Vident Advisory LLC reduced its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 27.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,669 shares of the medical technology company's stock after selling 5,204 shares during the quarter. Vident Advisory LLC's holdings in Stryker were worth $5,089,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. Capital A Wealth Management LLC bought a new position in shares of Stryker during the fourth quarter worth about $26,000. Goodman Advisory Group LLC bought a new position in shares of Stryker during the first quarter worth about $32,000. City Holding Co. grew its holdings in shares of Stryker by 528.6% during the first quarter. City Holding Co. now owns 88 shares of the medical technology company's stock worth $33,000 after buying an additional 74 shares in the last quarter. Smallwood Wealth Investment Management LLC bought a new position in shares of Stryker during the first quarter worth about $40,000. Finally, Itau Unibanco Holding S.A. bought a new position in shares of Stryker during the fourth quarter worth about $42,000. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Viju Menon sold 500 shares of the business's stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.20% of the company's stock.

Stryker Stock Performance

Shares of SYK traded down $1.76 during mid-day trading on Tuesday, reaching $389.65. The company's stock had a trading volume of 1,140,976 shares, compared to its average volume of 1,082,272. The stock has a market cap of $148.97 billion, a P/E ratio of 51.61, a PEG ratio of 2.85 and a beta of 0.93. The business has a 50-day simple moving average of $389.57 and a two-hundred day simple moving average of $379.45. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period last year, the firm posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker's dividend payout ratio (DPR) is presently 44.50%.

Analyst Ratings Changes

A number of research firms recently issued reports on SYK. Wall Street Zen upgraded Stryker from a "hold" rating to a "buy" rating in a report on Friday, July 18th. Sanford C. Bernstein set a $450.00 price objective on Stryker in a report on Monday, May 5th. Truist Financial set a $415.00 price objective on Stryker and gave the stock a "hold" rating in a report on Monday, August 4th. Needham & Company LLC increased their price target on Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Finally, BTIG Research reissued a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Fifteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Stryker has a consensus rating of "Moderate Buy" and a consensus target price of $430.10.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.